**6. Concluding remarks**

We suggest the investigators to combine different isolation methods to achieve the most optimal performance of CTC isolation and clinical trials for solid validation. The cooperation among medical oncologists and biomedical engineers are critically important for the future advances in CTC field. Genetic or molecular analysis, such as PCR for epigenetics or mutation of specific gene(s) or next‐generation sequencing for whole genome, whole exon, or chosen targeted genes will be the major directions for personalized cancer therapies. The advances of microfluidic devices will quickly solve the conventional problems of time‐consuming, sample‐ consuming, operator‐dependent, and marker‐dependent limitations.
